Results 81 to 90 of about 1,738 (143)

A pharmacovigilance study of Bruton's tyrosine kinase inhibitors: a multidimensional analysis based on FAERS and VigiBase. [PDF]

Front Immunol
Qu H, Jia Y, Liu Z, Li Z, Zhao X, Wu Z, Fan G, Lou Y.   +7 more
europepmc   +1 more source

BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. [PDF]

J Clin Exp Hematop
Kojima K, Watanabe S, Takeuchi A, Kunisawa N, Yoshida S.   +4 more
europepmc   +1 more source

Bone marrow progenitor cells and vascular endothelium : Studies on the in vivo differentiation capacity and the role of Bmx tyrosine kinase [PDF]

, 2004
Rajantie, Iiro
core  

X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including Pneumocystis jirovecii [PDF]

, 2014
Bonagura, V. R., Gough, J. D., Jongco, A. M., Moreau, J., Ponda, P., Rosenthal, D. W., Sarnataro, K.   +6 more
core   +3 more sources

Case Report: X-linked agammaglobulinemia with progressive neurodegeneration from immunological to neurological implications. [PDF]

Front Immunol
Chen X, Gu H, Piao Y, Ma Y, Zhao Y, Mao H, Wang Y, Deng J.   +7 more
europepmc   +1 more source

Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real-World Impact of Cardiovascular Adverse Events. [PDF]

Cancer Med
Obeng-Kusi M, De Nigris E, Leng S, Farooqui MZH, Yapici HO, Weimer I, Jiao W, Hyatt HW, Zhang X, Lodaya K, Dingli D.   +10 more
europepmc   +1 more source

The BMX Tyrosine Kinase : A Signal Mediator in Hematopoietic and Endothelial/Epithelial Cells [PDF]

, 2003
Ekman, Niklas
core  

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma. [PDF]

Blood Adv
Phillips T, Di M, Miller TA, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y.   +7 more
europepmc   +1 more source

Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient [PDF]

A Etzioni, A Moise, A Plebani, A Sawada, A Vargas-Hernandez, A Yoshino, AK Dobbs, D Vetrie, Daw-Yang Hwang, DM Stewart, E Lopez-Granados, E Stiehm, HD Ochs, Hung-Chun Chen, HW Eijkhout, I-Fang Wang, IM Pessach, IM Pessach, J Väliaho, Jer-Ming Chang, K Maekawa, L Yel, L Yel, Lee-Moay Lim, LM Endo, M Antar, ME Conley, ME Conley, ME Conley, ME Conley, ME Conley, MF Goldstein, MF Guill, N Basile, N Shinomiya, OC Bruton, S Nonoyama, S Tsukada, SP Kwan, T Ohno, Wei-Chiao Chang, Y Minegishi, Y Minegishi, Y Minegishi   +43 more
core   +1 more source

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. [PDF]

Blood Adv
Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfò L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL.   +30 more
europepmc   +1 more source